Objective: The aim of this investigation was to study the clinical efficacy and safety of Zhizhu Kuanzhong capsule in the treatment of functional dyspepsia and depression. Method: The Sixty four patients with functional dyspepsia and depression in our hospital from Jan 2013 to Feb 2014 were randomized into the control group (domperidone) and the observation group Zhizhu Kuanzhong capsule according to the random number

with 32 patients per group. The changes of dyspeptic symptom scores

depression scores and electrogastrogram on pre-and post-treatment

and the clinical efficacy

adverse reactions and recurrence rate in the two groups were observed and compared. Result: Compared with the control group

the dyspeptic symptom scores (3.6±1.3) VS (5.2±2.1)and depression scores (8.1±1.1) VS (15.1±1.8)were significantly decreased after treatment in the observation group (P<0.05);compared with the control group

the normal slow wave before meals (47.7±18.3) VS (40.8±15.6)

normal slow wave after meals (52.3±14.0) VS (46.1±15.2)

the main power ratio before meals and after meals (3.5±1.2) VS (2.6±1.0)

and gastric emptying time (2.6±0.1) VS (4.4±0.2) were significantly improved after treatment in the observation group (P<0.05);compared with the control group

the cure rate (75.0% VS 50.0%)and total effective rate (93.8% VS 75.0%)were significantly increased and the recurrence rate (3.1% VS 21.9%)significantly decreased in the observation group (P<0.05). There were no obvious adverse reactions in the both groups during the treatment period. Conclusion: The treatment of Zhizhu Kuanzhong capsule can significantly improve the gastric motility

with better anti-depressant efficacy and high safety

and is worthy of wide clinical promotion.